During the recent session, Icecure Medical Ltd (NASDAQ:ICCM)’s traded shares were 0.53 million. At the last check today, the stock’s price was $1.24, reflecting an intraday gain of 0.81% or $0.01. The 52-week high for the ICCM share is $1.57, that puts it down -26.61 from that peak though still a striking 61.29% gain since the share price plummeted to a 52-week low of $0.48. The company’s market capitalization is $67.93M, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 730.86K shares over the past three months.
Icecure Medical Ltd (ICCM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ICCM has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.07.
Icecure Medical Ltd (NASDAQ:ICCM) trade information
Icecure Medical Ltd (ICCM) registered a 0.81% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.81% in intraday trading to $1.24, hitting a weekly high. The stock’s 5-day price performance is 10.71%, and it has moved by 53.09% in 30 days. Based on these gigs, the overall price performance for the year is -0.80%. The short interest in Icecure Medical Ltd (NASDAQ:ICCM) is 0.28 million shares and it means that shorts have 0.46 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.5, which implies an increase of 50.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.5 and $2.5 respectively. As a result, ICCM is trading at a discount of -101.61% off the target high and -101.61% off the low.
Icecure Medical Ltd (ICCM) estimates and forecasts
Statistics show that Icecure Medical Ltd has outperformed its competitors in share price, compared to the industry in which it operates. Icecure Medical Ltd (ICCM) shares have gone up 69.86% during the last six months, with a year-to-date growth rate more than the industry average at 12.50% against 5.00. In the rating firms’ projections, revenue will increase 8.05% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.07M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 952.5k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.25M and 743k respectively. In this case, analysts expect current quarter sales to shrink by -14.94% and then jump by 28.20% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -0.26%. While earnings are projected to return 11.46% in 2025.
ICCM Dividends
Icecure Medical Ltd is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Icecure Medical Ltd (NASDAQ:ICCM)’s Major holders
The next largest institutional holding, with 66400.0 shares, is of RENAISSANCE TECHNOLOGIES LLC’s that is approximately 0.1421% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $49136.0.
